Pfizer inks immuno deal

Share this article:
Pfizer emerged from Q3 2013 with a 3% drop in earnings compared to the same period last year
Pfizer emerged from Q3 2013 with a 3% drop in earnings compared to the same period last year

Pfizer and Gliknik inked a deal worth $25 million up front, plus additional milestones that grant Pfizer worldwide rights to the private company's human intravenous immunoglobulin, GL-2045, which may be applied to autoimmune diseases.

FierceBiotech says the treatment in question's “big idea is that its version of FC fusion protein “can be used in much smaller quantities to provide the same or better therapeutic effect than IVIG has.”

Fierce also notes that the treatment bypasses human blood, and could put Pfizer “in a position to make an unlimited quantity to replace what is today a $7 billion product.”

Share this article:
close

Next Article in News

Email Newsletters

More in News

Five things for pharma marketers to know: Friday, August 22

Five things for pharma marketers to know: Friday, ...

Two new indications give Eliquis more juice, a new rule is making hydrocodone harder to get and the ALS Ice Bucket Challenge highlights a controversial aspects of drug discovery and ...

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.